Navigation Links
Kingfisher Healthcare Launches Breakthrough Product in Europe
Date:9/19/2007

LEUVEN, Belgium, September 19 /PRNewswire/ -- Kingfisher Healthcare (KFH) announces the launch of KFH Energy, a product to alleviate fatigue and pain, two common problems associated with chronic diseases such as post polio syndrome, fibromyalgia and multiple sclerosis. KFH Energy is a patented, high-tech medical device for home use.

The KFH Energy utilizes Bio-Electric Stimulation Therapy (BEST) to deliver extremely low currents to the body. BEST works by enhancing the physiological processes at cellular level, documented effects include:

- an increase in ATP production, the molecule that delivers energy to all cells in the body

- increased synthesis of proteins, the building blocks of the body

The founder and CEO of KFH, Dr Henk Snyman, said: "We are very proud to introduce such a superior and safe solution to the many people suffering from fatigue, pain and lack of stamina. We are dedicated to continuing research and are exploring further applications in ongoing clinical trials."

The 1st clinical trial showed excellent results in post polio patients, and KFH has decided to support further research into the puzzling deterioration that many polio patients experience later in life. Dr Snyman indicated: "We are therefore very pleased to announce the creation of an annual Marianne Liefers Post polio Research Award, to the value of CAD$5.000. An independent panel will decide each year which project to support, and it is also recognition of the tireless and dedicated way in which Mrs Liefers - one of the first patient to be treated - has helped us to discover the positive effects that KFH Energy can have in the lives of people who had polio as children.

Note to Editors:

KFH is a young healthcare company , developing its own pipeline of proprietary products. It utilizes a technology platform called BEST (Bio-Electric Stimulation Therapy), from which unique products are developed. These products alleviate specific symptoms associated with chronic conditions, including chronic fatigue in post polio syndrome, fibromyalgia, multiple sclerosis and others, and the healing of chronic wounds such as leg ulcers, decubitus ulcers, and others. For more information, including vodcast testimonials from patients, see http://www.kfhealth.com.


'/>"/>
SOURCE Kingfisher Healthcare
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Web-based reporting credited with states top healthcare ranking
2. Visions: Preizler offers insurers perspective on healthcare IT
3. Federal bill would set healthcare IT standards
4. IRS ruling could speed healthcare technology adoption
5. Bill would provide federal aid for healthcare IT
6. DHC 2007: Hayden says technology creates magic moment for healthcare delivery
7. Digital Healthcare Conference 2007: Mounting obstacles for health IT
8. Georgia healthcare system to install GEs radio frequency ID
9. GE Healthcare leads compact ultrasound market
10. CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare
11. Merge Healthcare suffers $258M loss in `06
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):